Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET-CT Imaging in Patients With CLDN18.2 Positive Solid Tumors

NCT04989010 is registered in ClinicalTrials.gov with Wuxi No. 4 People's Hospital as lead sponsor.

NCT NCT04989010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET-CT Imaging in Patients With CLDN18.2 Positive Solid Tumors
Lead sponsor
Wuxi No. 4 People's Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 1, 2021
Completion date
August 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult